Song Si-Min, Liu Qian-Min, Huang Xi, Chen Ping, Tao Min, Pei Xia, Wang Hua-Ning, Han Yan, Chen Jian-Guo, Hong Wei, Zhang Zhang-Jin
Department of Chinese Medicine, the University of Hong Kong-Shenzhen Hospital (HKU-SZH), Shenzhen, 518055, China.
Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Alzheimers Res Ther. 2025 Jun 23;17(1):140. doi: 10.1186/s13195-025-01781-z.
Both electroacupuncture (EA) and repetitive transcranial magnetic stimulation (rTMS) possess the potential in combating the progression of Alzheimer's disease (AD). In this study, we compared the effects of the two regimens as early long-term intervention in App mice, a new amyloid precursor protein (APP) knock-in model that recapitulates multiple AD-associated pathologies, including amyloid-β (Aβ) plaques, microgliosis, astrocytosis, dendritic and synaptic degeneration. The 2-month-old freely moving model mice randomly received EA or rTMS for 2~3 sessions a week for 6 months. Cognitive tests were conducted in Y maze and Barnes maze sequentially at the age of 4, 6, and 8 months. The cortex and hippocampus were dissected thereafter for neurohistological and molecular analysis. Both regimens markedly prevented cognitive deterioration at 6 months old. EA maintained its significant prevention to 8 months old, but rTMS did not. At this age, EA remarkably reduced Aβ burdens with particular dense-core plaques; rTMS had similar effects on Aβ plaques, but not on dense-core plaques. Both regimens displayed greater suppression on microgliosis in the cortex than in the hippocampus, and equivalently inhibited astrocytosis in the two brain regions. While both EA and rTMS protected against dendritic degeneration surrounding Aβ plaques, EA further mitigated synaptic loss. These results demonstrated that EA produced more long-lasting and broad-acting effects than rTMS in alleviating memory impairment and pathological products of AD. EA could serve as an early long-term intervention and rTMS as adjuvant therapy in slowing the progression of AD.
电针(EA)和重复经颅磁刺激(rTMS)在对抗阿尔茨海默病(AD)进展方面均具有潜力。在本研究中,我们比较了这两种治疗方案作为对App小鼠的早期长期干预的效果,App小鼠是一种新的淀粉样前体蛋白(APP)基因敲入模型,可重现多种与AD相关的病理变化,包括β淀粉样蛋白(Aβ)斑块、小胶质细胞增生、星形细胞增生、树突和突触退化。2月龄自由活动的模型小鼠被随机分为接受EA或rTMS治疗,每周2至3次,持续6个月。在4、6和8月龄时依次在Y迷宫和巴恩斯迷宫中进行认知测试。此后解剖皮质和海马进行神经组织学和分子分析。两种治疗方案均显著预防了6月龄时的认知衰退。EA在8月龄时仍保持显著的预防作用,但rTMS则没有。在这个年龄,EA显著降低了Aβ负荷,尤其是致密核心斑块;rTMS对Aβ斑块有类似作用,但对致密核心斑块无作用。两种治疗方案对皮质中小胶质细胞增生的抑制作用均大于海马,且对两个脑区的星形细胞增生的抑制作用相当。虽然EA和rTMS均能防止Aβ斑块周围的树突退化,但EA进一步减轻了突触损失。这些结果表明,在减轻AD的记忆损害和病理产物方面,EA比rTMS产生更持久、作用更广泛的效果。EA可作为早期长期干预措施,rTMS可作为辅助治疗来减缓AD的进展。